• XSTEM license deal possible in 2024
• Targinta develops tumour-directed cancer treatments in a hot field
• We initiate coverage with a fair value of
The full report is available here.
© Modular Finance, source
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.288 SEK | -6.49% |
|
+7.46% | +6.27% |
May. 24 | Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 23 | Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses | CI |
• XSTEM license deal possible in 2024
• Targinta develops tumour-directed cancer treatments in a hot field
• We initiate coverage with a fair value of
The full report is available here.
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
+6.27% | 16.57M | |
+18.09% | 45.01B | |
+46.51% | 40.96B | |
-8.38% | 38.62B | |
+34.66% | 32.6B | |
-8.34% | 27.49B | |
+16.10% | 27.17B | |
+49.73% | 14.61B | |
+36.71% | 12.95B | |
-6.60% | 11.36B |